Soligenix Inc (SNGX)

$1.23 0.00 (N/A)
Market Cap 12.61M
Revenue (ttm) 120,000.00
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,891.67%
Debt to Equity Ratio 0.00
Volume 171,600
Avg Vol 311,654
Day's Range N/A - N/A
Shares Out 10.09M
Stochastic %K 10%
Beta 1.95
Analysts Strong Buy
Price Target $17.50

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 538 8200
Fax: 609 452 6467
Address:
29 Emmons Drive, Suite B-10, Princeton, United States
uptrend2025
uptrend2025 Feb. 3 at 7:18 PM
$SNGX This one could pop soon
0 · Reply
Bhaddar1
Bhaddar1 Feb. 3 at 4:49 PM
$SNGX buy it xx
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 2 at 6:11 PM
$SNGX Builds Momentum in Fight Against Rare, Chronic Cancer https://ibn.fm/AExFL
0 · Reply
JB20901
JB20901 Jan. 30 at 10:19 PM
$SNGX perfect
0 · Reply
Bhaddar1
Bhaddar1 Jan. 30 at 9:33 PM
$APRE These dips are gift 🎁 And $SNGX $CRIS Buy and Hold $7
1 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 30 at 7:10 PM
$SNGX Positioning for Impact in Growing Rare-Disease Landscape https://ibn.fm/Cen9T
0 · Reply
7CM
7CM Jan. 30 at 2:19 PM
$SNGX
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 29 at 6:03 PM
BioMedNewsBreaks — $SNGX Targets Critical Gaps in CTCL Treatment with HyBryte(TM) https://ibn.fm/pnI2N
0 · Reply
jtabrizi
jtabrizi Jan. 28 at 7:31 PM
$SNGX added here
0 · Reply
rrch
rrch Jan. 28 at 4:41 PM
$SNGX want to see a European partner
0 · Reply
Latest News on SNGX
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 6 weeks ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Dec 17, 2025, 1:23 PM EST - 6 weeks ago

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 17, 2025, 7:30 AM EST - 6 weeks ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Dec 3, 2025, 8:30 AM EST - 2 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 19, 2025, 7:30 AM EST - 2 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Nov 7, 2025, 7:30 AM EST - 3 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Oct 14, 2025, 7:30 AM EDT - 4 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Oct 7, 2025, 7:30 AM EDT - 4 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 30, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 29, 2025, 4:05 PM EDT - 4 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 4 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Sep 23, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 4, 2025, 7:30 AM EDT - 5 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 1:03 PM EDT - 6 months ago

Why Is Soligenix Stock Soaring On Monday?

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 18, 2025, 7:30 AM EDT - 6 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Aug 8, 2025, 8:30 AM EDT - 6 months ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 8, 2025, 7:30 AM EDT - 7 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jul 1, 2025, 7:30 AM EDT - 7 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Jun 6, 2025, 9:37 AM EDT - 8 months ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 9, 2025, 7:30 AM EDT - 9 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Apr 14, 2025, 7:30 AM EDT - 10 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 8:30 AM EDT - 11 months ago

IBN Initiates Coverage of Soligenix Inc.

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 25, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 21, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Mar 6, 2025, 7:30 AM EST - 11 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Soligenix to Present at BIO CEO & Investor Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Soligenix to Present at Upcoming Investor Conferences

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 7, 2024, 7:30 AM EDT - 1 year ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix Announces Partnership with Sterling Pharma Solutions

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 16, 2024, 9:00 AM EDT - 1 year ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:46 PM EDT - 1 year ago

Soligenix stock rallies 400% on positive HyBryte trial results

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 12:11 PM EDT - 1 year ago

Crude Oil Down 1%; Soligenix Shares Surge

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Jul 9, 2024, 11:38 AM EDT - 1 year ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

uptrend2025
uptrend2025 Feb. 3 at 7:18 PM
$SNGX This one could pop soon
0 · Reply
Bhaddar1
Bhaddar1 Feb. 3 at 4:49 PM
$SNGX buy it xx
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 2 at 6:11 PM
$SNGX Builds Momentum in Fight Against Rare, Chronic Cancer https://ibn.fm/AExFL
0 · Reply
JB20901
JB20901 Jan. 30 at 10:19 PM
$SNGX perfect
0 · Reply
Bhaddar1
Bhaddar1 Jan. 30 at 9:33 PM
$APRE These dips are gift 🎁 And $SNGX $CRIS Buy and Hold $7
1 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 30 at 7:10 PM
$SNGX Positioning for Impact in Growing Rare-Disease Landscape https://ibn.fm/Cen9T
0 · Reply
7CM
7CM Jan. 30 at 2:19 PM
$SNGX
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 29 at 6:03 PM
BioMedNewsBreaks — $SNGX Targets Critical Gaps in CTCL Treatment with HyBryte(TM) https://ibn.fm/pnI2N
0 · Reply
jtabrizi
jtabrizi Jan. 28 at 7:31 PM
$SNGX added here
0 · Reply
rrch
rrch Jan. 28 at 4:41 PM
$SNGX want to see a European partner
0 · Reply
Tonyboner
Tonyboner Jan. 26 at 3:14 PM
$SNGX Look to re enter near catalyst
0 · Reply
Tonyboner
Tonyboner Jan. 26 at 3:14 PM
$SNGX Stopped out
0 · Reply
Tonyboner
Tonyboner Jan. 26 at 2:59 PM
$SNGX Too many warrants hanging for this to jump over $1.40S
0 · Reply
wolf_of_crypto_street
wolf_of_crypto_street Jan. 24 at 10:01 AM
$SNGX https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319720713&type=HTML&symbol=SNGX&cdn=de1cb7dfba57ee83de8137fa3c65f2e4&companyName=Soligenix+Inc.&formType=424B5&dateFiled=2026-01-23
0 · Reply
wolf_of_crypto_street
wolf_of_crypto_street Jan. 24 at 9:59 AM
$SNGX https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319720396&type=HTML&symbol=SNGX&cdn=61c3fefcd75694928a830d7f220f27d1&companyName=Soligenix+Inc.&formType=8-K&dateFiled=2026-01-23
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 23 at 8:30 PM
MissionIRNewsBreaks – RiVax(R) Positions $SNGX in Growing Biodefense Preparedness Efforts https://ibn.fm/tb4QK
0 · Reply
ppl_first
ppl_first Jan. 21 at 7:59 PM
$SNGX Advanced programs in rare disease and biodefense where procurement and regulation, not physician adoption, drive value. Commercial risk is secondary.
0 · Reply
Bhaddar1
Bhaddar1 Jan. 20 at 10:24 AM
$SNGX big 🗞️ on the way
0 · Reply
PTI127
PTI127 Jan. 19 at 8:30 PM
$SNGX @DaBullRunner @Bhaddar1 @topstockalerts
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 16 at 8:24 PM
$SNGX Announces Positive Phase 2 Data for Rare Inflammatory Disease https://nnw.fm/o46FD
0 · Reply
Bhaddar1
Bhaddar1 Jan. 16 at 7:19 PM
$SNGX big things on the way Don’t forget
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 15 at 6:08 PM
Michigan State University Research Says Suppressing Postoperative Pain Could Delay Healing $SNGX #BioMed #MichiganState #PostoperativePain https://ibn.fm/2rBOf
0 · Reply